PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Federal State Budget Institution \'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya\' of the Ministry of Health of the Russian Federation, Moscow, Russia. Electronic address: ldenisy@gmail.com.\', \'Federal State Budget Institution \'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya\' of the Ministry of Health of the Russian Federation, Moscow, Russia.\', \'Federal State Autonomous Educational Institution of Higher Education I M Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia.\', \'Federal State Budgetary Institution \'The Main Military Clinical Hospital named after N N Burdenko\' of the Ministry of Defence of the Russian Federation, Moscow, Russia.\', \'Branch No 7 of the Federal State Budgetary Institution \'The Main Military Clinical Hospital named after N N Burdenko\' of the Ministry of Defence of the Russian Federation, Moscow, Russia.\', \'48 Central Research Institute of the Ministry of Defence of the Russian Federation, Moscow, Russia.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S0140-6736(20)31866-310.1016/S0140-6736(20)31866-3
?:hasPublicationType
?:journal
  • Lancet (London, England)
is ?:pmid of
?:pmid
?:pmid
  • 32896291
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.
?:type
?:year
  • 2020

Metadata

Anon_0  
expand all